Can platinib be purchased in China for 47,000 yuan in 2024?

Pralsetinib (Pralsetinib), formerly known as BLU-667, is a selective RET inhibitor that can effectively target RET kinases, including RET fusion proteins. Phase 1 of the ARROW study established the recommended Phase 2 dose of oral platinib (400 mg once daily). Platinib has low affinity for off-target kinases.

In a biochemical analysis, platinib was 88 times more selective for RET than vascular endothelial growth factor receptor 2 (VEGFR 2), a tyrosine kinase receptor targeted by multiple kinase inhibitors including cabozantinib and vandetanib2. Based on the results of the registration phase 1/2 ARROW study, platinib is approved in many countries around the world (including the United States) for the treatment of metastatic RET fusion-positive non-small cell lung cancer, advanced or metastatic RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer.

The original drug Platinib has been launched in China, but it has not yet passed the relevant policies for inclusion in medical insurance. The price of 120 pills per box may be around RMB 60,000. For specific prices, please consult the local hospital pharmacy. The price of the European version of Platinib's original drug sold overseas may be around RMB 40,000 per box of 60 pills, and the U.S. version may be priced around RMB 150,000 per box (the price may fluctuate due to exchange rates), which is expensive. Generic Platinib drugs are also available for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. The price of 120 pills per box produced by a Lao pharmaceutical factory may be more than 4,000 yuan (the price may fluctuate due to exchange rate effects).